Use of idraparinux for extended prophylaxis of thromboembolism
AssigneeSanofi-Aventis
InventorGerard PILLION
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of idraparinux for the extended prophylaxis of thromboembolism, in particular for the prevention of the recurrence of thromboembolism during 6 months after permanent discontinuation of the treatment with this drug.
Claims10
A method for the prevention of the recurrence of thromboembolism after discontinuation of an initial treatment for thromboembolism of a patient, the method comprising administering an initial treatment to a patient of idraparinux sufficient to treat or prevent a thromboembolism and then discontinuing such treatment.
A method for lowering the incidence of thromboembolism after discontinuation of an initial treatment of a patient with an anticoagulant drug, the method comprising administering an initial treatment to a patient of idraparinux and then discontinuing such treatment.
Dependencies are inferred from the claim text.